Jaime Modiano
Oprichter bij ApopLogic Pharmaceuticals, Inc.
Profiel
Jaime F.
Modiano is the founder of ApopLogic Pharmaceuticals, Inc., which was founded in 2006.
He held the title of Scientist at the company.
Dr. Modiano's former job positions include being an Assistant Professor at Texas A&M University from 1995 to 1999, an Associate Professor at the University of Colorado Health Sciences Center in 2007, and a Senior Scientist at AMC Cancer Research Center.
Dr. Modiano's education history includes earning a doctorate degree from the University of Pennsylvania in 1991 and an undergraduate degree from El Colegio de México AC in 1981.
Actieve functies van Jaime Modiano
| Bedrijven | Functie | Begin |
|---|---|---|
ApopLogic Pharmaceuticals, Inc.
 ApopLogic Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology ApopLogic Pharmaceuticals, Inc. researches and develops pharmaceutical products. It focuses on the development and commercialization of B201, is a rationally-designed synthetic peptide dimer of a potent decapeptide bradykinin B1&B2 receptor antagonist that directly induces apoptosis of cancer cells that overexpress these receptors and AP-300 is used in the neo-adjuvant or adjuvant setting with standard-of-care agents to improve survival outcomes in humans and companion animals with any accessible solid tumor including carcinomas, sarcomas and lymphomas. The company was founded in 2006 by Richard C. Duke, Donald Bellgrau, Paul A. Bunn, Daniel Chan, Lajos Gera, Jaime F. Modiano and John M. Stewart and is headquartered in Aurora, CO. | Oprichter | 01-08-2006 |
Eerdere bekende functies van Jaime Modiano
| Bedrijven | Functie | Einde |
|---|---|---|
| University of Colorado Health Sciences Center | Corporate Officer/Principal | 01-01-2007 |
| Texas A&M University | Corporate Officer/Principal | 01-01-1999 |
| AMC Cancer Research Center | Corporate Officer/Principal | - |
Opleiding van Jaime Modiano
| University of Pennsylvania | Doctorate Degree |
| El Colegio de México AC | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 2 |
|---|---|
ApopLogic Pharmaceuticals, Inc.
ApopLogic Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology ApopLogic Pharmaceuticals, Inc. researches and develops pharmaceutical products. It focuses on the development and commercialization of B201, is a rationally-designed synthetic peptide dimer of a potent decapeptide bradykinin B1&B2 receptor antagonist that directly induces apoptosis of cancer cells that overexpress these receptors and AP-300 is used in the neo-adjuvant or adjuvant setting with standard-of-care agents to improve survival outcomes in humans and companion animals with any accessible solid tumor including carcinomas, sarcomas and lymphomas. The company was founded in 2006 by Richard C. Duke, Donald Bellgrau, Paul A. Bunn, Daniel Chan, Lajos Gera, Jaime F. Modiano and John M. Stewart and is headquartered in Aurora, CO. | Health Technology |
| AMC Cancer Research Center |
